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Plasma cell leukemia (PCL) was originally defined by the presence of both >20%
circulating plasma cells (PCs) and an absolute count >2 × 109/L PCs,1,2 although in
many studies the presence of only 1 of the above criteria was required.3-5 PCL may
be classified as primary when it presents de novo in patients without previous evi-
dence of multiple myeloma (MM) or secondary when it is presented as a leukemic
transformation of a previously recognized MM. Primary PCL is a rare entity with
an incidence of 2 to 4% of MM6-8 and is associated with a worse prognosis than
MM. Its median survival, in a large epidemiological study, was only 4 months.7
However, with the use of novel drugs upfront, median survival ranging from 18 to
36 months has been reported.9-15
The presence of circulating PCs, identified by cytology,16 multiparameter flow
cytometry17,18 or slide-based immunofluorescence,19 is also associated with a worse
prognosis in myeloma patients not fulfilling the criteria of PCL. The presence of cir-
culating PCs is also a risk factor of progression to active disease in patients with
The presence of circulating plasma cells in patients with multiplemyeloma is considered a marker for highly proliferative disease. Inthe study herein, the impact of circulating plasma cells assessed by
cytology on survival of patients with multiple myeloma was analyzed.
Wright-Giemsa stained peripheral blood smears of 482 patients with
newly diagnosed myeloma or plasma cell leukemia were reviewed and
patients were classified into 4 categories according to the percentage of
circulating plasma cells: 0%, 1-4%, 5-20%, and plasma cell leukemia
with the following frequencies: 382 (79.2%), 83 (17.2%), 12 (2.5%) and
5 (1.0%), respectively. Median overall survival according to the circulat-
ing plasma cells group was 47, 50, 6 and 14 months, respectively. At mul-
tivariate analysis, the presence of 5 to 20% circulating plasma cells was
associated with a worse overall survival (relative risk 4.9, 95%CI 2.6–9.3)
independently of age, creatinine, the Durie-Salmon system stage and the
International Staging System (ISS) stage. Patients with ≥5% circulating
plasma cells had lower platelet counts (median 86x109/L vs. 214x109/L,
P<0.0001) and higher bone marrow plasma cells (median 53% vs. 36%,
P=0.004). The presence of ≥5% circulating plasma cells in patients with
multiple myeloma has a similar adverse prognostic impact as plasma cell
leukemia.
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ABSTRACT
monoclonal gammopathy of undetermined significance20
and smoldering MM.21 It has been suggested that MM
patients with circulating PCs, even below 20%, could
have the same bad prognosis as patients with PCL. Indeed,
a lower cutoff of ≥5% or ≥0.5 x109/L of nucleated periph-
eral blood cells to redefine PCL has been proposed.3 In the
present study, the impact of the presence of circulating
PCs assessed by cytology on the survival of patients with
MM was analyzed.
Methods
Requirements to enter the study were a diagnosis of sympto-
matic MM or primary PCL according to the International
Myeloma Working Group (IMWG) criteria22 between January
2008 and December 2013 in 5 University Hospitals from
Catalonia, and to have peripheral blood smears at diagnosis avail-
able for review. The study was approved by the Ethic Committee
of the Hospital de la Santa Creu i Sant Pau and was conducted
according to the declaration of Helsinki. Clinical data including
age, sex, myeloma isotype, percentage of bone marrow plasma
cells, lactate dehydrogenase (LDH), Durie-Salmon and ISS stages,
as well as initial treatment and follow up, were collected from
medical records. Cytogenetic analysis was performed according to
local policies and patients were treated according to regional pro-
tocols. Wright-Giemsa stained peripheral blood smears were
reviewed by 5 experienced hematologists on peripheral blood
cytology. A minimum of 100 nucleated cells per smear were sys-
tematically counted. Each sample was analyzed by a single mor-
phologist, with each following the same common criteria.
The primary endpoint was overall survival (OS) measured from
the date of diagnosis to the date of death or last follow up.
Differences in demographics and baseline characteristics were
compared using the two-sided Fisher's exact test for categorical
variables and the Mann-Whitney U test for continuous variables.
Survival analysis was performed using the Kaplan-Meier method
and differences were tested for statistical significance using the
log-rank test. Multivariate analysis was conducted using the Cox
proportional hazards model. All calculations were performed
using the software SPSS® statistics version 22.
Results
Clinical characteristics
The study cohort included 482 patients diagnosed with
MM between January 2008 and December 2013. The
median age at diagnosis was 69 years (range 28 to 92
years). Two hundred and sixty (53.9%) of the patients
were males. The median follow up was 28 months for the
whole cohort and 38 months for the patients alive. Two
hundred and thirty-one (47.9%) patients died during fol-
low up. First-line therapy was based on bortezomib com-
binations in 230 (47.7%) patients, alkylating agents with
glucocorticoids in 114 (23.7%) patients, vincristine, dox-
orubicin (adriamycin), and dexamethasone (VAD) or
VAD-like chemotherapy in 60 (12.4%), immunomodula-
tory-based combinations in 26 (5.4%), high-dose dexam-
ethasone in 4 (0.8%), and only palliative care in 48 (9.9%)
patients. One hundred and fifty-six (32.4%) patients
received autologous stem cell transplantation as part of
their first-line treatment. Twelve (2.5%) patients received
allogeneic stem cell transplantation during the course of
the disease.
Clinical characteristics at diagnosis according to the cir-
culating PCs group are summarized in Table 1. Differences
in age, sex, myeloma isotope, LDH, Durie-Salmon and ISS
stages between the 4 groups were not statistically signifi-
cant. However, patients within the 5 to 20% circulating
PCs group had lower platelet counts (median 86x109/L vs.
214x109/L, P<0.0001) and a higher proportion of bone
marrow PCs (median 53% vs. 36%, P=0.004).
The 5 patients with >20% circulating PCs were initially
treated with bortezomib and dexamethasone (2 patients);
bortezomib, cyclophosphamide and dexamethasone (1
patient); melphalan and prednisone (1 patient); and borte-
zomib, melphalan and prednisone (1 patient). Of the 12
patients with 5-20% circulating PCs, 1 died the day after
diagnosis and only received supportive care, the remaining
11 patients were initially treated as follows: bortezomib
and dexamethasone (6 patients); bortezomib, thalidomide
and dexamethasone (2 patients); VAD (1 patient); borte-
zomib, melphalan and prednisone (1 patient); and
cyclophosphamide and steroids (1 patient). One patient
with >20% circulating PCs and 3 patients with 5-20% cir-
culating PCs received an autologous stem cell transplanta-
tion as consolidation.
Risk factors for overall survival in the overall cohort
According to the percentage of circulating PCs, 4 groups
were considered for the analysis of survival: no circulating
plasma cells, 382 (79.2%) patients; 1 to 4% circulating
plasma cells, 83 (17.2%) patients; 5 to 20% circulating
plasma cells, 12 (2.5%) patients; and classical PCL group
(>20% or >2x109/L plasma cells), 5 (1%) patients. A
patient with 15% circulating PCs but an absolute circulat-
ing PC count of 2.7x109/L was included in the classical PCL
group.
The median OS of patients with no circulating PCs, 1 to
4%, 5 to 20% and >20% were 47 (95%CI 38.6–55.4)
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Figure 1. Overall survival according to the circulating plasma cells (PCs) group
in patients with multiple myeloma (P<0.001).
<5% PCs
≥5% PCs
months, 50 (95%CI 31.0–68.9) months, 6 (95%CI 0.9–
11.1) months and 14 (95%CI 9.7–18.3) months, respec-
tively (Figure 1) (P<0.001).
In the univariate analysis, the other factors associated
with a worse survival together with circulating PCs were
age older than 65 years at diagnosis, creatinine >2 mg/dL,
treatment with new drugs upfront (proteasome inhibitors
or immunodulatory drugs), and Durie-Salmon and ISS
advanced stages. Cytogenetic data was not included in the
survival analysis due to the lack of such data in most
patients. The 5 patients with classical PCL were excluded
from the multivariate analysis. The finding of 5 to 20%
circulating plasma cells, age older than 65 years, Durie-
Salmon III, creatinine >2 mg/dL, and ISS 3 retained their
significance in the multivariate analysis (Table 2).
Risk factors for overall survival in patients treated with
novel agents upfront
Two hundred and sixty five of the 482 (54.9%) patients
were treated upfront with proteasome inhibitors and/or
inmunomodulatory drugs. Of these, 192 (72.5%) patients
had 0% circulating PCs, 61 (23.0%) patients had 1 to 4%
circulating PCs, 9 (3.4%) patients had 5 to 20% circulating
PCs and 3 (1.1%) patients had a diagnosis of classical PCL.
One hundred and ten (41.5%) patients treated with novel
Circulating plasma cells in myeloma
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Table 1. Clinical characteristics according to the number of circulating plasma cells group.
Circulating plasma cells 0% 1-4% 5-20% >20%
N (% overall) 382 (79.2) 83 (17.2) 12 (2.5) 5 (1.0)
Male, n (%) 218 (57.1) 33 (39.7) 5 (42) 4 (80)
Age, y. median (range) 70.1 (32-92) 68 (28-88) 65 (48-85) 62 (49-80)
Heavy chain, n (%):
Ig G 230 (60.2) 46 (55.4) 6 (50) 3 (60)
Ig A 92 (24.1) 18 (21.7) 2 (17) 0
light chain only 57 (14.9) 18 (21.7) 4 (33) 2 (40)
IgD or IgM 3 (0.7) 1 (1.2) 0 0
Light chain, n (%):
κ 247 (64.6) 54 (65.1) 5 (42) 2 (40)
l 135 (35.3) 29 (34.9) 7 (58) 3 (60)
Hemoglobin, g/L. Median (range) 104 (56–171) 99 (68-139) 92 (65-144) 103 (40-129)
WBC. x109/L. Median (range) 6.2 (1.7–22.6) 5.9 (0.9-16.2) 6.3 (3.7-7.0) 24 (63-8)
Platelets. x109/L. Median (range) 214 (50–558)* 223 (58-493) 86 (24-174)* 138 (28-242)
Calcium, mg/dL. Median (range) 9.3 (7.2–14.8) 9.4 (7.3-14.2) 10.1 (8.6-15.8) 9.4 (9.0-11.4)
Creatinine, mg/dL. Median (range) 1.1 (0.3–11.9) 1.1 (0.5-12.2) 1.5 (0.6-8.0) 1.1 (0.6-6.8)
Lytic lesions. n (%):
None 172 (45.0) 39 (46.9) 7 (58) 3 (60)
One to 3 186 (48.7) 43 (51.8) 4 (33) 1 (20)
More than 3 24 (6.3) 1 (1.2) 1 (8) 1 (20)
D-S stage. n (%):
I 55 (14.4) 7 (8.4) 1 (8) 2 (40)
II 156 (40.8) 41 (49.4) 3 (25) 0
III 171 (44.7) 35 (42.2) 8 (67) 3 (60)
B (creat >2mg/dL) 64 (16.7) 18 (21.7) 5 (42)
β2-m, mg/L. median (range) 4.6 (1–48) 5.0 (1.7-35.1) 5.8 (2.9-31) 6.7 (4.9-7)
Albumin, g/L. median (range) 37.0 (15-48.9) 35.7 (20-43) 31 (24-45) 38.1 (29-47)
ISS stage. n (%):
I 85 (22.2) 13 (15.7) 1 (8) 0
II 132 (34.6) 28 (33.7) 4 (33) 1 (20)
III 137 (35.8) 36 (43.4) 7 (58) 3 (60)
NA 28 (7.3) 6 (7.2) 1 (20)
LDH UNL, n (%) 59 (15.4) 11 (13.2) 4 (33) 2 (40)
Bone marrow PCs, %. median (range) 36 (1-100)** 48 (2-100) 53 (38-90)** 43 (18-95)
Extramedullary disease, n (%) 77 (20.1) 11 (13.2) 3 (25) 1 (20)
Cytogenetics, n/assessed (%)
t(4;14) 7/164 (4.2) 5/31 (16.1) 0/4 (0) 0/3 (0)
del 17p. 17/177 (9.6) 3/39 (7.7) 1/8 (12)  1/3 (33)
*P=0.001. **P=0.006. WBC: White blood cells; D-S: Durie-Salmon; β2-m: beta 2 microglobulin; ISS: International Staging System; LDH: Lactate dehydrogenase; UNL: Upper normal
limit; PCs: plasma cells.
agents upfront died during follow up and their median OS
was 50 (95% CI 38–61) months.
In patients treated with novel agents upfront, the medi-
an OS in cases with 0%, 1 to 4%, 5 to 20% and PCL were
58 (95% CI NR) months, 60 (95% CI 33–86) months, 22
(95% CI 0–65) months and 14 (95% CI 1–26) months,
respectively. When only 2 groups were considered, <5%
and ≥5% circulating PCs, median OS were 58 (95% CI 46
– 69) months and 14 (95% CI 0.4 – 27) months (Figure 2).
Together with the percentage of circulating PCs, the
other factors associated with a worse OS in univariate
analysis were creatinine >2mg/dL and ISS stage II or III. A
trend was observed in patients >65 years old and 
Durie-Salmon stage III. Taking into account the aforemen-
tioned variables, having  ≥5% circulating PCs alone was
the only fact which maintained statistical significance in
the multivariate analysis (Table 3). LDH was not included
in the multivariate analysis due to the lack of statistical
significance or even a trend in univariate analysis (RR 1.1,
95% CI 0.7–1.9, P=0.467).
Discussion
This study aimed to address the impact of circulating
PCs on the survival of patients with MM. Seventeen per
cent of patients had between 1 and 4% circulating plasma
cells. That finding was not associated with other clinical
characteristics and had no impact on survival. There was
a completely different picture for the 2.5% of patients
with 5 to 20% circulating PCs. Such patients had lower
platelet counts, higher bone marrow infiltration and,
importantly, a shorter survival independent of other
known clinical  prognostic factors. In fact, the median OS
of 6 months observed in these patients is closer to that of
patients with the “classical” definition of PCL. When the
analysis was restricted to patients treated with novel
agents upfront, the impact of circulating PCs was consis-
tent with the whole cohort. The differences in OS
observed between patients with 5-20% circulating PCs
and >20% circulating PCs (6 vs. 14 months) may be
explained by the low number of cases in both groups.
Although the presence of circulating PCs has been pre-
viously associated with survival, conventional cytology
has been used for their assessment in only one study.16 In
that case, patients with circulating plasma cells constituted
14.1% of the overall series and had a median survival of
25 months. The results of the present study are consistent
with the ominous prognostic impact of peripheral blood
plasmacytosis; however, the definition of  a high-risk
group found was different; ≥2% circulating PCs in the
study by An et al. and ≥5% circulating PCs in the study
herein.
Using multiparameter flow cytometry, the presence of
circulating PCs has also been associated with survival.17,18,23
In the study from the Mayo Clinic,17 24% of patients had
more than 400 circulating PCs. Such patients had a median
OS of 32 months versus not reached in patients with 400
or less circulating PCs. In another study from the same
institution, which in this case used slide-based immuno-
fluorescence microscopy for plasma cell quantification,19
54% of patients with >4% PCs were identified. These
patients had a median survival of 2.4 years compared to
4.4 years in patients with fewer circulating PCs. The afore-
mentioned studies used much more sensitive techniques
than those used in the present; this may explain the differ-
ent percentages of patients with circulating PCs identified
M. Granell et al.
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Figure 2. Overall survival according to the circulating plasma cells (PCs) in
patients with multiple myeloma and plasma cell leukemia (PCL) treated with
novel drugs upfront (P<0.001). 
Table 2. Risk factors for overall survival, overall cohort.
Univariate* Multivariate*
RR 95% CI P RR 95% CI P
5-20% circulating PCs 4.0 2.1 – 7.3 <.001 4.9 2.6 – 9.3 <0.001
>65 years 2.1 1.6 – 2.8 <.001 2.0 1.5 – 2.8 <0.001
D-S stage III 1.6 1.2 – 2.0 0.001 1.7 1.2 – 2.2 <0.001
Creatinine >2mg/mL 1.7 1.3 – 2.3 0.001 1.5 1.1 – 2.1 0.010
ISS II or III 2.4 1.6 – 3.5 <.001 1.7 1.1 – 2.6 0.014
New drugs upfront 1.5 1.1 – 2.0 <.001 1.6 1.2 – 2.2 <0.001
LDH UNL 1.3 0.9 – 1.9 0.07 1.4 0.9 – 1.9 0.09
*Cox model. RR: relative risk; CI: confidence interval; PCs: plasma cells; D-S: Durie-Salmon; ISS: International staging System; LDH: lactate dehydrogenase. UNL: Upper normal
limit.  
0% PC
1-4% PCs
5-20% PCs
PCL
in those studies in comparison with the present one. 
Despite these findings, the definition of PCL has been
based on standard morphological examination of periph-
eral blood.3 In comparison with flow cytometry and
immunofluorescence, conventional cytology identifies a
smaller number of patients with an extremely poor prog-
nosis. Additionally, conventional cytology has the advan-
tage of being a simple and inexpensive technique that can
be applied in any clinical laboratory worldwide. However,
it has a limitation; conventional cytology is not able to
identify the clonality of PCs, as can be achieved by flow
cytometry and immunofluorescence. This may hamper
the specificity of conventional cytology since polyclonal
reactive PCs may be rarely detected in some patients with
MM.24,25
The presence of t(4;14), del(17p), amp(1q21) and
del(1p21) in malignant PCs are adverse prognostic factors
in MM.26,27 Indeed, adverse cytogenetics together with ISS
3 and/or high LDH identifies a group of patients with an
ultra-high risk of MM.28 Several of these genetic abnormal-
ities, particularly del(17p)9 and chromosome 1 alter-
ations29 are more frequent in PCL than in MM. In the series
presented herein, del(17p) by fluorescence in situ
hybridization (FISH) was observed in 1 of 7 patients with
5 to 20% circulating PCs and 1 of 2 patients with >20%
circulating PCs. A limitation of the present study is that,
due to the lack of cytogenetic data in most patients, the
prognostic impact of unfavorable cytogenetic abnormali-
ties and the revised ISS28 could not be analyzed.
As highlighted in the last consensus by IMWG,3 the
diagnosis of PCL has been classically done on the basis of
the presence of >20% circulating PCs and/or an absolute
count >2 × 109/L PCs.  However, lower peripheral blood
PC counts, as showed in our study (that is, ≥5% peripheral
blood plasma cells), should be considered as a diagnostic
criteria of PCL (“PCL-like” myeloma or early PCL), due to
the independent and strong prognostic impact.
Prospective multicenter analysis with translational and
correlative studies into the biology of these patients is
encouraged as well as risk-oriented therapeutic strate-
gies.30,31 Careful examination of peripheral blood by con-
ventional microscopy should be done for all patients with
MM in daily clinical practice. 
In conclusion, the presence of ≥5% circulating PCs by
conventional cytology easily identifies a group of patients
with myeloma with a prognosis as poor as that of PCL,
suggesting that the diagnosis of PCL should be revisited. If
confirmed in other series, especially in prospective studies
of uniformly treated patients, such patients may benefit
from a distinct and more intensified therapeutic approach.
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Table 3. Factors associated with overall survival in patients treated with novel drugs upfront.
Univariate* Multivariate*
RR 95% CI P RR 95% CI P
≥5% circulating PCs 4.8 2.5 – 9.1 <0.001 4.5 2.4 – 8.8 <0.001
>65 years 1.4 0.9 – 2.1 0.060 1.3 0.8 – 1.9 0.186
D-S stage III 1.3 0.9 – 1.9 0.102 1.3 0.9 – 2.0 0.132
Creatinine >2mg/mL 1.8 1.2 – 2.8 0.007 1.5 0.9 – 2.4 0.082
ISS II or III 1.9 1.1 – 3.3 0.010 1.6 0.9 – 2.7 0.092
*Cox model. RR: relative risk; CI: confidence interval; PCs: plasma cells; D-S: Durie-Salmon; ISS: International staging System; LDH: lactate dehydrogenase.
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